FDA Authorizes Monoclonal Antibody for Treatment of COVID-19. The U.S. FDA issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients.

Dexamethasone : the first life-saving drug for COVID-19 patients Clinical trials make it possible to evaluate whether a treatment improves outcomes. Developing a hypothesis, for example if treatment A is better than standard treatment B, clinical trials enable understanding of the role of an intervention in improving patient care. In the...

Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events.

Comparative study of PPI for symptom relief in patients with reflux esophagitis: Some of the present study demonstrated that esomeprazole gave faster symptom relief than pantoprazole, lansoprazole and omeprazole. Because: Esomeprazole has been shown to have a faster onset of anti-secretory...

Usual Adult Dose for Fever Oral: Doses may be given as a single or repeated dose as follows: Immediate-release: 325 mg to 1 g orally every 4 to 6 hours Minimum Dosing Interval: every 4 hoursMaximum Single Dose: 1000 mgMaximum Dose: 4 g/24 hours   Extended-Release: 1300 mg orally every 8 hours Maximum dose...

UMHS Lipid Therapy Guideline Recommendations (2014) The guidelines showed that Rosuvastatin is the most potent statins with respect to lowering LDL, followed by atorvastatin, pitavastatin, simvastatin and lovastatin. Rosuvastatin 40 mg reducing LDL cholesterol by 63% whereas Atorvastatin 80...

C.      Insulin resistance: Lipophilic statins may have adverse metabolic consequences that include impaired insulin secretion and promotion of insulin resistance. Hydrophilic statins ·        pravastatin improves insulin sensitivity in some patients...